In addition to Scotiabank, Biogen also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Biogen (NASDAQ ...

In a report released today, Jay Olson from Oppenheimer reiterated a Buy rating on Biogen, with a price target of $205.00. The company’s shares closed today at $128.00. Take advantage of TipRanks ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

礼来制药收跌14.14%，创2000年8月份以来最差单日表现。减肥药概念股中，除了礼来之外，ANAB、VTYX、福泰制药、美国制药ETF、渤健BIIB、硕迪生物、Hims也跌9.63%-0.16%。安进、罗氏控股ADR、雅培则至多收涨0.86%，辉瑞和阿斯利康ADR至多涨1.32%，诺和诺德ADR涨7.45%，VKTX涨11.54%。 返回搜狐，查看更多 ...

Of the companies that reported their results last week, 18 beat analysts’ earnings forecasts, while 3 missed. On the revenue ...

公司管理层在第二季度财报会议中强调，医生对大量患者处方该药物，这表明医疗界对其信心不断提升。此外，约60%的患者享有商业保险覆盖，40%由政府医保计划覆盖，且超过90%的患者无需支付自付费用，这些因素共同促成了药物的成功。

In an exclusive Q&A, a Biogen exec discussed the developer's quest to 'rapidly' bring its experimental SMA therapy salanersen ...